StockData
Aardvark Therapeutics, Inc. logo

Aardvark Therapeutics, Inc. (AARD) stock

AARDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$1.00+0.09 (+9.89%)

Close on Nov 19, 2026Market cap $21.88MP/E –Yield –

Aardvark Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Aardvark Therapeutics's free cash flow for the twelve months ending Dec 31, 2025 was -$54.27M. For fiscal 2025 it was -$54.27M.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$54.27M–
FY2024Dec 31, 2024-$18.20M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025-$16.81M–
Q3 FY2025Sep 30, 2025-$16.13M–
Q2 FY2025Jun 30, 2025-$9.94M–
Q1 FY2025Mar 31, 2025-$11.39M–
Q4 FY2024Dec 31, 2024-$7.73M–
Q3 FY2024Sep 30, 2024-$3.96M–
Q2 FY2024Jun 30, 2024-$4.31M–
Q1 FY2024Mar 31, 2024-$2.20M–

More Aardvark Therapeutics figures

See a number that looks wrong?